These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
190 related items for PubMed ID: 6438859
1. [Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences]. Schmähl D, Habs M, Tacchi AM. Urologe A; 1984 Sep; 23(5):291-6. PubMed ID: 6438859 [Abstract] [Full Text] [Related]
2. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna). Habs MR, Schmähl D. Cancer; 1983 Feb 15; 51(4):606-9. PubMed ID: 6401591 [Abstract] [Full Text] [Related]
3. Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna. Schmähl D, Habs MR. Cancer Treat Rev; 1983 Sep 15; 10 Suppl A():57-61. PubMed ID: 6414697 [No Abstract] [Full Text] [Related]
4. Prevention of cyclophosphamide cystitis with 2-mercaptoethane sodium sulfonate: a histologic study. Freedman A, Ehrlich RM, Ljung BM. J Urol; 1984 Sep 15; 132(3):580-2. PubMed ID: 6433044 [Abstract] [Full Text] [Related]
5. The prevention of cyclophosphamide-induced bladder swelling in the rat by I.V. administration of sodium-2-mercaptoethane sulfonate. Kedar A, Simpson CL, Williams P, Moore R, Tritsch G, Murphy GP. Res Commun Chem Pathol Pharmacol; 1980 Aug 15; 29(2):339-48. PubMed ID: 6774389 [Abstract] [Full Text] [Related]
6. Effect of the uroprotector sodium 2-mercaptoethane sulfonate (Mesna) on the proliferation of the bladder urothelium in the rat after administration of cyclophosphamide. Kunze E, Köhnecke B, Engelhardt W, Steinröder H, Brock N, Pohl J. Urol Int; 1984 Aug 15; 39(2):61-7. PubMed ID: 6426112 [Abstract] [Full Text] [Related]
7. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)]. Brock N, Stekar J. Arzneimittelforschung; 1982 Aug 15; 32(5):486-7. PubMed ID: 6809014 [Abstract] [Full Text] [Related]
8. Delayed development of bladder cancer in male SD rats induced with N-nitroso-N-butyl-N-(4-hydroxybutyl)amine following concomitant administration of sodium 2-mercaptoethane sulfonate. Berger MR, Schmähl D. Cancer Lett; 1986 Sep 15; 32(3):313-21. PubMed ID: 3094932 [Abstract] [Full Text] [Related]
9. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Brock N, Pohl J, Stekar J, Scheef W. Eur J Cancer Clin Oncol; 1982 Dec 15; 18(12):1377-87. PubMed ID: 6819957 [Abstract] [Full Text] [Related]
10. Comparison of reduced glutathione with 2-mercaptoethane sulfonate to prevent cyclophosphamide-induced urotoxicity. Cavalletti E, Tofanetti O, Zunino F. Cancer Lett; 1986 Jul 15; 32(1):1-6. PubMed ID: 3091245 [Abstract] [Full Text] [Related]
11. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics. Brock N, Pohl J. IARC Sci Publ; 1986 Jul 15; (78):269-79. PubMed ID: 3108156 [Abstract] [Full Text] [Related]
12. The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis. Ehrlich RM, Freedman A, Goldsobel AB, Stiehm ER. J Urol; 1984 May 15; 131(5):960-2. PubMed ID: 6423841 [Abstract] [Full Text] [Related]
13. Interaction of Mesna (2-mercaptoethane sulfonate) with the mutagenicity of cyclophosphamide in vitro and in vivo. Lähdetie J, Räty R, Sorsa M. Mutat Res; 1990 Sep 15; 245(1):27-32. PubMed ID: 2118231 [Abstract] [Full Text] [Related]
14. Sodium 2-mercaptoethane sulfonate protection against cyclophosphamide-induced teratogenicity in rats. Slott VL, Hales BF. Toxicol Appl Pharmacol; 1986 Jan 15; 82(1):80-6. PubMed ID: 3080822 [Abstract] [Full Text] [Related]
15. [Autoradiographic studies on the protective effect of mesna in the urinary bladder mucosa of the rat during administration of cyclophosphamide (preliminary communication)]. Kunze E, Köhnecke B, Engelhardt W, Brock N, Pohl J. Arzneimittelforschung; 1983 Jan 15; 33(6):853-4. PubMed ID: 6412725 [Abstract] [Full Text] [Related]
16. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. Andriole GL, Sandlund JT, Miser JS, Arasi V, Linehan M, Magrath IT. J Clin Oncol; 1987 May 15; 5(5):799-803. PubMed ID: 3106585 [Abstract] [Full Text] [Related]
17. N-acetylcysteine and sodium 2-mercaptoethane sulfonate as sources of urinary thiol groups in the rat. Ormstad K, Ohno Y. Cancer Res; 1984 Sep 15; 44(9):3797-800. PubMed ID: 6430554 [Abstract] [Full Text] [Related]
18. Delay of bladder cancer induction in rats treated with N-nitroso-N-butyl-N-(4-hydroxybutyl)amine by administration of sodium-2-mercaptoethanesulfonate (Mesna). Tacchi AM, Schmähl D, Habs M. Cancer Lett; 1984 Feb 15; 22(1):89-94. PubMed ID: 6421479 [Abstract] [Full Text] [Related]
19. Lack of effects of sodium 2-mercaptoethane sulfonate (mesna) on Ochratoxin A induced renal tumorigenicity following life-time oral administration of Ochratoxin A in DA and Lewis rats. Son WC, Kamino K, Lee YS, Kang KS. Toxicol Lett; 2003 Apr 30; 142(1-2):19-27. PubMed ID: 12765235 [Abstract] [Full Text] [Related]
20. Effective prevention of the nephrotoxicity of cis-platin (CDDP) by administration of sodium 2-mercaptoethane-sulfonate (MESNA) in rats. Kempf SR, Ivankovic S, Wiessler M, Schmähl D. Br J Cancer; 1985 Dec 30; 52(6):937-9. PubMed ID: 3935152 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]